CHOP和R-CHOP方案治疗弥漫性大B细胞淋巴瘤的成本-效果分析

目的：评价CHOP和利妥昔单抗联合CHOP（即R-CHOP）两种化疗治疗初治弥漫性大B细胞淋巴瘤的经济学效果。方法：46例患者随机分为2组,CHOP组16例,接受每3周为1个疗程的环磷酰胺＋阿霉素＋长春新碱＋口服泼尼松的CHOP治疗方案;R-CHOP组30例,接受在每个疗程开始的第1天联合使用利妥西单抗的R-CHOP治疗方案,平均疗程均为4.5;评价2组的疗效及不良反应,并进行成本-效果分析。结果：CHOP和R-CHOP组总有效率分别为81.3%和90.0%,总成本分别为367.51和25825.96元;成本-效果比分别为4.52和286.96,两者间增量成本-效果比为2926.26;不良反应发生率两组比较相似（68.8%vs73.3%）,差异无显著性（P=0.742）。结论：R-CHOP方案治疗CD20阳性的弥漫大B细胞型NHL与单纯CHOP方案相比总有效率略高,但CHOP方案成本-效果优于R-CHOP方案。

Cost- effectiveness Analysis of CHOP and R- CHOP Regimen for Native Diffuse Large B - cell Lymphoma

OBJECTIVE： To evaluate the cost - effectiveness outcome of R - CHOP （the combination of Rituximab and CHOP） and CHOP regimen in the therapy of native diffuse large B - cell lymphoma （DLBCL）. METHODS： A retrospective analysis was used to compare R - CHOP and CHOP regimen according to pharmacoeeonomic cost - effectiveness method. A total of 46 patients in SYSUCC were enrolled： 16 received CHOP regimen （CHOP group） and 30 received R- CHOP regimen （R - CHOP group）. RESULTS： The C/E ratio of CHOP and R - CHOP group were 4.52 and 286.96,respectively. And the incremental cost effectiveness ratio was 2 926.26. CONCLUSION ： The efficacy of CHOP regimen in the treatment of DLBCL was comparable to the R - CHOP regimen, but the cost - effectiveness of the former was superior of the two regimens.